Introduction
Recent advances in molecular biology have indicated that dopamine, an important neurotransmitter implicated in several neuropsychiatric disorders, can interact with at least five dopamine receptors (see [ l ] for a review). Among these, the dopamine D3 receptor (D3R) appears to be an important target for neuroleptics, which it recognizes dopamine with high affinity [2-41 and is selectively expressed in the brain limbic system [2, 5] , defects of which are likely to be involved in mood and cognitive disturbances. In addition, preliminary genetic studies suggest a loose association between its gene and schizophrenia [6] . T h e identification of D3R-mediated responses is therefore important for selecting drugs that interact specifically with this receptor, and which could be used to ascertain its physiological and pathological significance.
T h e use of heterologous cell expression systems has allowed the identification of secondmessenger pathways for dopamine receptor subtypes. Dopamine D, and D5 receptors (D,R and DSR) stimulate adenylate cyclase, whereas dopamine D2 and D4 receptors (D2R and D4R) inhibit this enzyme and are functionally coupled to additional effector systems, including phospholipase C and AZr or CaZt and K+ channels [ 13. All these latter effects are mediated via G-proteins of the G,/G, group. Evidence for such coupling of D3R to G-proteins has long been lacking: D3R stimulation has been shown to inhibit cyclic AMP formation inconsistently [2, 3, . Among possible explanations for the lack of D3R coupling to conventional effector systems, it could be argued that the recipient cells used in previous studies may not be appropriate, either because the D3R is incorrectly processed or integrated in the membrane or because the cells do not express the adequate G-protein or effector system.
In view of the above considerations, we have used a transfected neuroblastoma-glioma hybrid cell line (NG 108-15) known to express a wide 11 To whom correspondence should be addressed.
variety of G-proteins and effectors and stably expressing a high level of D3R [7] . Activation of D3R inhibits cyclic AMP formation and increases mitogenesis, two D3R-mediated responses allowing identification of selective agonists and antagonists that have been used to ascribe physiological functions of the D3R.
Inhibition of cyclic AMP accumulation
We isolated, by limiting dilution of our original transfected NG 108-15 cell line [7] , a subclone in which D3R stimulation led to strong inhibition of cyclic AMP formation ( Figure 1A ). Quinpirole inhibited cyclic AMP accumulation triggered by 10 pM forskolin in a concentration-dependent fashion, with an EDSo 0.27 nM and a maximum inhibition of about 50%. The effect of quinpirole was antagonized by haloperidol and reproduced by dopamine ( -34%), pramipexole ( -36%) and quinelorane (-44%) . No effects were seen in the parental wild-type NG 108 15 cells.
The reasons why such an inhibition of cyclic AMP formation could not be observed previously using the same cell line [7] are unclear. NG 108 15 cells show phenotypical variations accompanied by morphological changes [ 12, 131 . In other words, the expressions of adenylate cyclase isoenzymes or G-proteins could have varied. In support of a change in the G-protein, we observed that the proportion of the high-affinity site for dopamine was higher, and that G T P produced a stronger shift in the dopamine inhibition curve than previously.
Thus, in agreement with their structural homologies, D3R, DZR and D4R seem to use similar transduction pathways. T h e differences observed among various cell lines may be related to different combinations of G-protein and effector isoforms.
Stimulation of mitogenesis and its potentiation by cyclic AMP
Another biological effect resulting from D3R stimulation in transfected NG 108-15 is mitogenesis, which is evaluated by measuring the incorporation of [3H] thymidine during DNA syn- Rather unexpectedly, the quinpirole-induced mitogenesis was markedly enhanced when cyclic AMP was increased by forskolin ( Figure 1B) . Forskolin increased the D3R-mediated response induced by quinpirole (0.1 pM) to 250-350% of basal values, compared with 140-200% without forskolin, with no significant changes in EC50 values. This effect actually involves cyclic AMP, since it was reproduced by two permeable cyclic AMP analogues, and depends upon the activation of the cyclic AMP-dependent kinase, being blocked by an inhibitor of this enzyme (not shown).
Several mechanisms probably contribute to mitogenesis, and potent mitogenic factors acting through G-protein-coupled receptors increase phosphatidylinositol turnover and inhibit cyclic AMP formation. Mitogenesis induction has also been observed in a CHO cell line transfected with dopamine D2R or D3R cDNAs [8, 14] . Since quinpirole does not activate phospholipase C [7] , the activation of this pathway is not required, which is in line with other observations [15, 16] . Furthermore, our data suggest that inhibition of adenylate cyclase does not play a major role in the mitogenic response, which occurs in the presence of forskolin and cyclic AMP analogues, a conclusion already suggested for the D2 receptor [14] , as well as for the D3R [8] expressed in CHO cells. In CHO cells, D2R activation has been shown to result in stimulation of tyrosine phosphorylations and mitogen-activated protein kinases [14, 17] , a transduction pathway that might also be activated by D3R, but involving different components, since the D2R-mediated mitogenesis is not affected by cyclic AMP analogues.
Identification of selective D, receptor agonists
Co-activation of the cyclic AMP pathway together with the D3R represents a major improvement, in terms of analytical pharmacology, that dramatically increases the signal-to-noise ratio of the mitogenic D3R-mediated response. This improvement allows measurement, with high precision, of the potency of various agonists, including those with a very low intrinsic activity [ 18,191. Various compounds of different chemical classes were compared for their ability to induce mitogenesis in cells expressing D2R or D3R (Table 1) . Most agonists produced a similar maximum response to dopamine.
Partial agonism at D3R was detected for 1-
, which was a full agonist at D2R.
was a partial agonist at D2R but a full agonist at D3R. C F 25397 was a partial agonist at both receptors. Interestingly, (+)-UH 232, a ligand with partial D3R selectivity [2, 3] and previously considered to be an antagonist [7, 20] , dose-dependently increased mitogenesis in cells expressing D3R, with an ECSo of 7.6 nM and a maximum response corresponding to 28% of that produced by quinpirole ( Table 1 ). The response induced by (+)-UH 232 was reversibly antagonized by nafadotride [19] , a D3R antagonist [21, 22] . Unlike other agonists with a high intrinsic activity, the EC,,, value of (+)-UH 232 for the mitogenesis response is close to its Ki of 11 nM measured in binding studies [2, 3] , which is consistent with its lower intrinsic activity. (+)-UH 232 also antagonized the D3-induced mitogenesis induced by dopamine [7] and quinpirole [19] , with a K, value equal to its binding affinity at D3R. In NG 108-15 cells expressing D3R, (+)-UH 232 also inhibited the forskolin-induced cyclic AMP accumulation by 22%, compared with the 53% inhibition produced by quinpirole in the same experiments [19] , and the effect of (+)-UH 232 was completely reversed by addition of 1 pM nafadotride. Although the intrinsic activity of (+)-UH 232, measured at D3R for two different responses, is low, it may produce significant D3R activation in cells expressing a high level of D3R. A partial agonist such as (+)-UH 232 may act as a regulator of dopamine transmission through D3R, acting as an activator when the level of dopamine is low and as an inhibitor in other situations.
Comparison between agonists also revealed selective compounds (Table 1) . Bromocriptine was the most D2R-selective compound, with a 10-fold selectivity. Dopamine itself was 15 times more potent at D3R than at D2R. PD 128,907 was the most selective compound for the D3R, with a 
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dopamine synthesis [23, 24] . This hypothesis is in agreement with the behavioural activations produced by D3R-preferring antagonists (see below).
Nafadotride, a potent D3 receptorpreferring antagonist
Nafadotride is a novel, potent and partially selective D3R antagonist [21, 22] . It has a 10-fold selectivity for D3R in binding studies, as well as in the mitogenesis test, in which it behaves as a pure antagonist (Table 2 ). Compared with haloperidol, a D2R-preferring antipsychotic, the behavioural profile of nafadotride is characterized by stimulation, at dosages of 0.2-1 mg/kg, of climbing behaviour of mice and of the locomotor activity of rats habituated to their environment (Table 2 ). In contrast, nafadotride exerts typical D2R-blocking responses at much higher dosage: for instance, about 100-fold higher dosages are required to observe catalepsy. The paradoxical behavioural stimulant properties of nafadotride are not shared by haloperidol, but have also been observed with other compounds displaying some degree of D3R versus D2R selectivity, but signifi- Table 2 In vitro and in vivo potencies of nafadotride compared with haloperidol Data are from [22] Test Nafodotride Haloperidol [25] or U99 194A, a compound of so far unknown structure [23] . Being produced by other D3R antagonists, including the pure antagonist nafadotride, these paradoxical stimulating properties in animal models do not result from a partial agonism, as it may have been advocated in the case of (+)-UH 232.
Since nafadotride in higher doses clearly causes increased dopamine neuron activity (evidenced by an increased homovanillic acid level) (Table 2) , it seems more likely that the locomotor stimulation results from blockade of a subset of post-synaptic dopamine receptors mediating tonic behavioural inhibition than from enhanced dopamine neuron activity. Consideration of these data, together with those obtained with agonists, leads to the postulate that a subpopulation of mesolimbic dopaminergic neurons exerts, via activation of presumably post-synaptic D3R, inhibition of locomotor activity. Such a role was previously assumed for a subpopulation of Dz-like receptors, mainly because of the discrepancy between the effective doses of dopamine agonists required to inhibit behavioural manifestations and dopamine release in brain (reviewed in [25] ).
Opposing roles for D2 and D3 receptors on neurotensin gene expression in the nucleus accumbens
T h e D3R is expressed in at least half of mediumsized neurotensin neurons in the ventromedial area of the shell subdivision of the nucleus accumbens [26, 27] . In the absence of highly selective D3R ligands, the role of dopamine innervation on neurotensin neuron was assessed by simultaneous blockade of D2R and D3R using haloperidol or sulpiride in rather high dosage [26] . In agreement with previous studies [28] , these agents induced a marked activation of neurotensin gene expression in DzR-rich areas, e.g. the dorsal striatum or the shell cone of the nucleus accumbens. In contrast, both agents had the opposite effect in the ventromedial shell, an area selectively expressing D3R: there the preexisting neurotensin mRNA signal was markedly decreased. A variety of other antipsychotics appear to trigger similar changes. In contrast, nafadotride at low dosage (1 mg/kg) decreased neurotensin mRNA only in the ventromedial shell, without affecting this marker in dorsal striatum and the shell cone of the nucleus accumbens, supporting the theory that, in subterritories of the shell, the D3R exerts a tonic stimulation of neurotensin gene expression, an effect opposite to that exerted in other striatal subdivisions by DzR.
These observations -that dopamine may exert opposite effects via D2R and D3R, and that D3R-preferring antagonists display behavioural stimulant properties in rodents -suggest that these drugs might display unique efficacy against the negative symptomatology of schizophrenia. Assuming that overactive dopaminergic transmission results in positive symptoms (hallucinations, delusion) via the D2R and negative symptoms (impoverished thought and affect) via the D3R, the greater efficacy of available antipsychotics against the former may be ascribed to their higher affinity for DzR than for D3R.
Conclusions
The use of a neuroblastoma as a recipient cell line for D3R expression revealed both opposite and synergistic interactions between cyclic AMP and the D3R: whereas D3R stimulation inhibits cyclic AMP formation, increasing this second messenger potentiates the mitogenic D3R-mediated response. Since the mitogenic response does not result from inhibition of cyclic AMP formation, it seems that another yet unidentified independent pathway, possibly involving the mitogen-activated proteins, can contribute to D3R intracellular signalling.
Apart from the cyclic AMP-dependent kinase, the components of the D3R-cyclic AMP interactions are not yet known, but might be operant in neurons co-expressing the D3R and receptors activating the cyclic AMP cascade, such as DIR. Indeed, both DIR and D3R are highly expressed in the shell subdivision of the nucleus accumbens and, particularly, in the islands of Calleja, where all granules cells express these two receptors [27, 29] . Thus, in these brain regions, an opposite interaction may occur between DIR and D3R for biological functions involving cyclic AMP as a main second messenger, whereas synergistic interactions may occur when the other pathway is involved. On the other hand, opposing effects of DzR and D3R on neurotensin gene expression can be explained if the signalling of these receptors in neurotensin neurons involves the two different pathways.
Such hypotheses might be validated when the signalling pathways of the D3R are better characterized, especially those of the native
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receptor in neurons. T h i s task will be facilitated using more selective agonists a n d antagonists, which t h e functional tests described here may help to select.
